ImmuPharma (IMM) Share Price, News & Analysis

Company Overview

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

Key Stats

• Today's Range: 3 to 3.99
• 50-Day Range: 3.21 to 4.47
• 52-Week Range: 3 to 11.50
• Volume: 4.38 million shs
• Average Volume: 2.47 million shs
• Market Capitalization: £22.01 million
• P/E Ratio: N/A
• Dividend Yield: 0.77%
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Last Earnings: 9/15/2026
• Today: 11/03/2026

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: LON:IMM
• CIK: N/A
• Web: www.immupharma.org
• Phone: +44-20-71524080
• Fax: N/A
• Employees: 13
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): GBX (0.83)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -£2.51 million
• Net Margins: 3,519.56%
• Pretax Margin: N/A
• Return on Equity: -559.87%
• Return on Assets: -43.00%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.89
• Quick Ratio: 1.03

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: GBX 0.17 per share
• Price / Cash Flow: 20.50
• Book Value: GBX 0.65 per share
• Price / Book: 5.45

Miscellaneous

• Outstanding Shares: 625,286,000
• Free Float: N/A
• Market Cap: £22.01 million
• Optionable: Not Optionable
• Beta: 3.02